Uncategorized

The role of pharma sales reps has changed in recent years, however, physicians still view reps as the leading influence on their relationships with biopharma companies, according to the recently released J.D. Power and Associates 2013 Physician Manufacturer Experience Study—Oncology.  The study is the first in a series that will examine physician satisfaction with biopharmaceutical manufacturers.  The oncology study looks at oncologist and hematologist satisfaction based on the following factors: sales representative interactions; contributions to advancing medical care; medical marketing practices; patient education programs and materials; and service process.

The Food and Drug Administration, acting on a law signed by President Obama in 2012, has launched the third phase of an initiative to increase patient participation in the regulation of drugs and medical devices. On a Wednesday in April, the agency went live with a new website aimed at demystifying the regulatory process for consumers and patient advocates.

NEW YORK (Reuters) – As the clock ticks down to the start of a U.S. healthcare overhaul, companies from device makers to hospital chains have been surprised to see Americans make even fewer trips to the doctor’s office.

The US Food and Drug Administration (FDA) has released two long-awaited guidance documents regarding the appeals process to be used by medical device manufacturers that have received a rejection by the agency.

The US Food and Drug Administration has published a report updating its plans for a nationwide medical device post-market surveillance system, including implementation of a Unique Device Identification (UDI) framework.

The refurbished medical equipment market is slated to be worth $9 billion by 2018, building at an annual growth rate of 8.2 percent, according to a new report from Transparency Market Research.

US regulators are preparing to revisit a now-withdrawn draft guidance on the clearance of medical devices through the 510(k) premarket notification pathway, and are looking for industry’s help in formulating a new guidance document meant to eventually take its place.

When the FDA approved Duchesnay USA’s Diclegis for morning sickness a few weeks ago, the drug became the only product available that was developed specifically for the treatment of nausea and vomiting that occurs during pregnancy, or NVP, in decades.  Bendectin was on the market thirty years ago to treat NVP, but was taken off the market after the drug was linked to hundreds of lawsuits claiming that Bendectin caused birth defects, however, this turned out to be a false alarm. In 1983, the company voluntarily withdrew Bendectin.

A jury of ten in Kentucky found Advanced Bionics strictly liable and negligent for the manufacture and sale of a class III medical device, known as a cochlear implant. The jury also awarded puntiive damages against Advanced Bionics (parent company Sonova).

Workshop Dates:  28–29 September 2013

2013 RAPS Convergence Dates:  30 September –2 October 2013